INTEGRATIVE BIOINFORMATICS AND PHARMACOINFORMATIC APPROACHES IN PERSONALIZED DRUG DISCOVERY: EMERGING COMPUTATIONAL STRATEGIES FOR PRECISION MEDICINE

Abstract

Significant changes in computational biology and pharmaceutical sciences have led to a revolutionary change in the current drug discovery process and the systems of precision medicine. In the current work, integrated bioinformatics an pharmacoinformatics strategies were explored to elucidate their contribution in the process of computational drug discovery and personalized therapeutics, with the help of benchmark datasets of Davis and KIBA. Data preprocessing, molecular interaction assessment, affinity prediction analysis, and comparative evaluation of drug–target interaction patterns were used to take a computational approach to the study. These selected datasets were large scale datasets of
molecular information such as compound isomeric SMILES, protein target sequences and binding affinity values, which made it possible to study predictive therapeutic relationships in a computational pharmacology system. Results showed significant difference in molecular interaction patterns and affinity distributions between both sets of data, promising the use of computational methods to aid in therapeutic screening and predictive pharmacological modelling. The KIBA dataset was also more diverse in terms of its molecular structures and interaction densities, suggesting its potential for
more effective application in artificial intelligence-based therapeutic prediction and machine learning-based pharmaceutical analysis. Furthermore, sequence analysis using bioinformatics confirmed the role of molecular targeting, identification of biomarkers, and systems pharmacology under precision medicine frameworks. The study also identified integrated computational strategies that could be more effective in the field of drug discovery, in terms of efficiency, specificity of therapeutic targets, and predictive safety assessment, with a reduced experimental complexity during the course of pharmaceutical development. The results highlight the emerging significance of integrating bioinformatics, pharmacoinformatics, and artificial intelligence in the present-day healthcare landscape, offering a boost to the field of personalized medicine and computational therapeutics. Overall, the study finds that the integrated computational frameworks have significant promise to revolutionize future pharmaceutical innovation, predictive drug discovery and personalized therapeutic development.